RRAGC and cardiomyopathy: Similarly, haploinsufficiency of mtor failed to exert therapeutic effect on the rragc KI model, as indicated by persistent cardiac pump dysfunction, unchanged cardiomyopathy marker expression, impaired growth, and reduced survival in double mutants (Figure 6D–F and Figure S4B).